![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Radiation Therapy Oncology Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00048997 |
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Lung Cancer |
Procedure: observation Radiation: radiation therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control |
Official Title: | A Phase III Comparison Of Prophylactic Cranial Irradiation Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer |
Estimated Enrollment: | 1058 |
Study Start Date: | September 2002 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm I: Experimental
Patients undergo prophylactic cranial irradiation 5 days a week for 3 weeks.
|
Radiation: radiation therapy
Given 5 days a week for 3 weeks
|
Arm II: No Intervention
Patients undergo observation.
|
Procedure: observation
Patients undergo observation.
|
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease stage (IIIA vs IIIB), histology (non-squamous cell vs squamous cell), and prior surgery (yes vs no). Patients are randomized to 1 of 2 treatment arms.
Patients are followed 3 months during the first year, every 6 months for 2-3 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 1,058 patients (529 per treatment arm) will be accrued for this study within 36 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of stage IIIA or IIIB non-small cell lung cancer
Complete response, partial response, or stable disease after definitive locoregional therapy (thoracic radiotherapy) with or without systemic chemotherapy and/or surgery (chemotherapy alone is not considered definitive therapy)
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, Arizona | |
Arizona Oncology Services Foundation | |
Phoenix, Arizona, United States, 85013 | |
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn | |
Scottsdale, Arizona, United States, 85251 | |
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea | |
Scottsdale, Arizona, United States, 85260 | |
United States, Illinois | |
Resurrection Medical Center | |
Chicago, Illinois, United States, 60631 | |
United States, Maine | |
Central Maine Comprehensive Cancer Center at Central Maine Medical Center | |
Lewiston, Maine, United States, 04240 | |
Maine Center for Cancer Medicine and Blood Disorders - Scarborough | |
Scarborough, Maine, United States, 04074 | |
United States, Maryland | |
Shore Regional Cancer Center at Memorial Hospital - Easton | |
Easton, Maryland, United States, 21601 | |
United States, Massachusetts | |
MetroWest Medical Center - Framingham Union Hospital | |
Framingham, Massachusetts, United States, 01702 | |
United States, Michigan | |
Josephine Ford Cancer Center at Henry Ford Hospital | |
Detroit, Michigan, United States, 48202 | |
United States, New Jersey | |
Cancer Institute of New Jersey at Cooper University Hospital - Camden | |
Camden, New Jersey, United States, 08103 | |
United States, Pennsylvania | |
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center | |
Wilkes-Barre, Pennsylvania, United States, 18711 | |
Geisinger Cancer Institute at Geisinger Health | |
Danville, Pennsylvania, United States, 17822-0001 | |
United States, Utah | |
Huntsman Cancer Institute at University of Utah | |
Salt Lake City, Utah, United States, 84112 | |
United States, Washington | |
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | |
Yakima, Washington, United States, 98902 |
Study Chair: | Elizabeth M. Gore, MD | Medical College of Wisconsin |
Study Chair: | James A. Bonner, MD | Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham |
Responsible Party: | Radiation Therapy Oncology Group ( Walter John Curran, Jr ) |
Study ID Numbers: | CDR0000257200, RTOG-0214, ECOG-RTOG-0214 |
Study First Received: | November 12, 2002 |
Last Updated: | April 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00048997 History of Changes |
Health Authority: | United States: Federal Government |
stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer |
Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases Neoplasm Metastasis |
Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |